GuruFocus Updates (Free subscription) | 12/08/2009
By insider. CFO of Hemispherx Biopharma Inc ( HEB ) Charles Thomas Iii Bernhardt buys 2,000 shares of HEB on 12/07/2009 at an average price of $0.56 a share. Read more » »
PR News Wire (Free subscription) | 12/08/2009
MEDIA, Pa., Dec. 8 /PRNewswire/ -- Shepherd, Finkelman, Miller & Shah, LLP (http://www.sfmslaw.com; e-mail: jmiller@sfmslaw.com), a law firm with offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin, has filed a lawsuit seeking class action status in the United States District Court for the Eastern District of Pennsylvania against Hemispherx Biopharma, Inc....
GuruFocus Updates (Free subscription) | 12/07/2009
By insider. CEO, 10% Owner of Hemispherx Biopharma Inc ( HEB ) William A Carter buys 30,000 shares of HEB on 12/07/2009 at an average price of $0.57 a share. Read more » »
The Street (Free subscription) | 12/04/2009
Biotech reporter Adam Feuerstein answers reader email about Hemispherx Biopharma, Cel-Sci and other stocks.
Market Wire (Free subscription) | 12/02/2009
NEW YORK, NY (MARKET WIRE) The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of all purchasers of Hemispherx Biopharma Inc. ("Hemispherx") (NYSE Amex: HEB) securities between February 18, 2009 and October 30, 2009, inclusive (the "Class Period").
Stock Market Analysis (Free subscription) | 12/07/2009
... Oculus Innovative Sciences, Inc. (OCLS) - No News 7. Uranium Resources, Inc. (URRE) - No News 8. Hemispherx Biopharma, Inc. (HEB) - News 9. Continental Airlines, Inc. (CAL) - News 10. Bare Escentuals, Inc. (BARE) - No News 11. BioCryst Pharmaceuticals, Inc. (BCRX) - No News 12. Ultra Silver ProShares (AGQ) 13. Mercadolibre, Inc. (MELI) - News 14. DayStar Technologies Inc. (DSTI) - No News...
Market Wire (Free subscription) | 12/04/2009
OKLAHOMA CITY, OK (MARKET WIRE) On November 10, 2009, a class action lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania against Hemispherx Biopharma, Inc. (AMEX: HEB). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series...
Volume Spike Investor (Free subscription) | 12/02/2009
Hemispherx Biopharma, Inc. (AMEX: HEB) lost almost half of its value last night and is still getting crushed this morning. The company announced that the FDA has denied its Ampligen treatment as a treatment for chronic fatigue syndrome. The FDA said the two key studies did not prove the drugs efficacy and recommended that another [...]
Rocky Mount Telegram - Business (Free subscription) | 12/02/2009
PHILADELPHIA — Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration decline...
Rocky Mount Telegram - Business (Free subscription) | 12/02/2009
PHILADELPHIA — Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration decline...
Stock Market Analysis (Free subscription) | 12/03/2009
... SeaChange International Inc. (SEAC) Allied Irish Banks plc (AIB) Collective Brands, Inc. (PSS) Hemispherx Biopharma, Inc. (HEB) Pre Market Stock Losers - 12/3/09 Sigma Designs, Inc. (SIGM) - Sigma Designs Q3 lags Street view; shares fall Synopsys Inc. (SNPS) - Synopsys forecasts weak first quarter; shares down The Children's Place Retail Stores, Inc. (PLCE) - The Children's Place Reports...
Tired of ME (Free subscription) | 12/02/2009
Source: The Street Date: 1 december 2009 Author: Adam Feuerstein URL: The Street Hemispherx BioPharma(HEB Quote) said late Tuesday night that the Food and Drug Administration refused to approve the experimental drug Ampligen for use in patients with chronic fatigue syndrome.
Miami Herald (Free subscription) | 12/02/2009
Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration declined approval for the biotechnology company's experimental intravenous drug Ampligen as a treatment for chronic fatigue syndrome.
kansascity.com (Free subscription) | 12/02/2009
Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration declined approval for the biotechnology company's experimental intravenous drug Ampligen as a treatment for chronic fatigue syndrome.
